An article from Neurology Today discusses the recent meeting of the Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) in which the panel voted that the evidence is inadequate to demonstrate that beta amyloid PET imaging improves Alzheimer outcomes.
The article also highlights the findings from a recent white paper completed by ICER evaluating the diagnostic value and clinical benefits of testing for Alzheimer’s Disease that Steve presented to MEDCAC. The purpose of the white paper was to help inform future research so that it is possible to evaluate different tests for Alzheimer’s disease in a way that will generate “adequate” evidence for not only patients and clinicians, but for insurers as well.